Neuroprotective efficacy of P7C3 compounds in primate hippocampus

Melissa D Bauman, Cynthia Schumann, Erin L. Carlson, Sandra L. Taylor, Edwin Vázquez-Rosa, Coral J. Cintrón-Pérez, Min Kyoo Shin, Noelle S. Williams, Andrew A. Pieper

Research output: Contribution to journalArticle

4 Citations (Scopus)

Abstract

There is a critical need for translating basic science discoveries into new therapeutics for patients suffering from difficult to treat neuropsychiatric and neurodegenerative conditions. Previously, a target-agnostic in vivo screen in mice identified P7C3 aminopropyl carbazole as capable of enhancing the net magnitude of postnatal neurogenesis by protecting young neurons from death. Subsequently, neuroprotective efficacy of P7C3 compounds in a broad spectrum of preclinical rodent models has also been observed. An important next step in translating this work to patients is to determine whether P7C3 compounds exhibit similar efficacy in primates. Adult male rhesus monkeys received daily oral P7C3-A20 or vehicle for 38 weeks. During weeks 2–11, monkeys received weekly injection of 5′-bromo-2-deoxyuridine (BrdU) to label newborn cells, the majority of which would normally die over the following 27 weeks. BrdU+ cells were quantified using unbiased stereology. Separately in mice, the proneurogenic efficacy of P7C3-A20 was compared to that of NSI-189, a proneurogenic drug currently in clinical trials for patients with major depression. Orally-administered P7C3-A20 provided sustained plasma exposure, was well-tolerated, and elevated the survival of hippocampal BrdU+ cells in nonhuman primates without adverse central or peripheral tissue effects. In mice, NSI-189 was shown to be pro-proliferative, and P7C3-A20 elevated the net magnitude of hippocampal neurogenesis to a greater degree than NSI-189 through its distinct mechanism of promoting neuronal survival. This pilot study provides evidence that P7C3-A20 safely protects neurons in nonhuman primates, suggesting that the neuroprotective efficacy of P7C3 compounds is likely to translate to humans as well.

Original languageEnglish (US)
Article number202
JournalTranslational Psychiatry
Volume8
Issue number1
DOIs
StatePublished - Dec 1 2018

Fingerprint

Bromodeoxyuridine
Primates
Hippocampus
Neurogenesis
Neurons
Macaca mulatta
Haplorhini
Rodentia
Clinical Trials
Newborn Infant
Injections
Survival
Pharmaceutical Preparations
P7C3 compound
Therapeutics

ASJC Scopus subject areas

  • Psychiatry and Mental health
  • Cellular and Molecular Neuroscience
  • Biological Psychiatry

Cite this

Bauman, M. D., Schumann, C., Carlson, E. L., Taylor, S. L., Vázquez-Rosa, E., Cintrón-Pérez, C. J., ... Pieper, A. A. (2018). Neuroprotective efficacy of P7C3 compounds in primate hippocampus. Translational Psychiatry, 8(1), [202]. https://doi.org/10.1038/s41398-018-0244-1

Neuroprotective efficacy of P7C3 compounds in primate hippocampus. / Bauman, Melissa D; Schumann, Cynthia; Carlson, Erin L.; Taylor, Sandra L.; Vázquez-Rosa, Edwin; Cintrón-Pérez, Coral J.; Shin, Min Kyoo; Williams, Noelle S.; Pieper, Andrew A.

In: Translational Psychiatry, Vol. 8, No. 1, 202, 01.12.2018.

Research output: Contribution to journalArticle

Bauman, MD, Schumann, C, Carlson, EL, Taylor, SL, Vázquez-Rosa, E, Cintrón-Pérez, CJ, Shin, MK, Williams, NS & Pieper, AA 2018, 'Neuroprotective efficacy of P7C3 compounds in primate hippocampus', Translational Psychiatry, vol. 8, no. 1, 202. https://doi.org/10.1038/s41398-018-0244-1
Bauman, Melissa D ; Schumann, Cynthia ; Carlson, Erin L. ; Taylor, Sandra L. ; Vázquez-Rosa, Edwin ; Cintrón-Pérez, Coral J. ; Shin, Min Kyoo ; Williams, Noelle S. ; Pieper, Andrew A. / Neuroprotective efficacy of P7C3 compounds in primate hippocampus. In: Translational Psychiatry. 2018 ; Vol. 8, No. 1.
@article{f28203e4ad2c42fa835a7eba648e8fa2,
title = "Neuroprotective efficacy of P7C3 compounds in primate hippocampus",
abstract = "There is a critical need for translating basic science discoveries into new therapeutics for patients suffering from difficult to treat neuropsychiatric and neurodegenerative conditions. Previously, a target-agnostic in vivo screen in mice identified P7C3 aminopropyl carbazole as capable of enhancing the net magnitude of postnatal neurogenesis by protecting young neurons from death. Subsequently, neuroprotective efficacy of P7C3 compounds in a broad spectrum of preclinical rodent models has also been observed. An important next step in translating this work to patients is to determine whether P7C3 compounds exhibit similar efficacy in primates. Adult male rhesus monkeys received daily oral P7C3-A20 or vehicle for 38 weeks. During weeks 2–11, monkeys received weekly injection of 5′-bromo-2-deoxyuridine (BrdU) to label newborn cells, the majority of which would normally die over the following 27 weeks. BrdU+ cells were quantified using unbiased stereology. Separately in mice, the proneurogenic efficacy of P7C3-A20 was compared to that of NSI-189, a proneurogenic drug currently in clinical trials for patients with major depression. Orally-administered P7C3-A20 provided sustained plasma exposure, was well-tolerated, and elevated the survival of hippocampal BrdU+ cells in nonhuman primates without adverse central or peripheral tissue effects. In mice, NSI-189 was shown to be pro-proliferative, and P7C3-A20 elevated the net magnitude of hippocampal neurogenesis to a greater degree than NSI-189 through its distinct mechanism of promoting neuronal survival. This pilot study provides evidence that P7C3-A20 safely protects neurons in nonhuman primates, suggesting that the neuroprotective efficacy of P7C3 compounds is likely to translate to humans as well.",
author = "Bauman, {Melissa D} and Cynthia Schumann and Carlson, {Erin L.} and Taylor, {Sandra L.} and Edwin V{\'a}zquez-Rosa and Cintr{\'o}n-P{\'e}rez, {Coral J.} and Shin, {Min Kyoo} and Williams, {Noelle S.} and Pieper, {Andrew A.}",
year = "2018",
month = "12",
day = "1",
doi = "10.1038/s41398-018-0244-1",
language = "English (US)",
volume = "8",
journal = "Translational Psychiatry",
issn = "2158-3188",
publisher = "Nature Publishing Group",
number = "1",

}

TY - JOUR

T1 - Neuroprotective efficacy of P7C3 compounds in primate hippocampus

AU - Bauman, Melissa D

AU - Schumann, Cynthia

AU - Carlson, Erin L.

AU - Taylor, Sandra L.

AU - Vázquez-Rosa, Edwin

AU - Cintrón-Pérez, Coral J.

AU - Shin, Min Kyoo

AU - Williams, Noelle S.

AU - Pieper, Andrew A.

PY - 2018/12/1

Y1 - 2018/12/1

N2 - There is a critical need for translating basic science discoveries into new therapeutics for patients suffering from difficult to treat neuropsychiatric and neurodegenerative conditions. Previously, a target-agnostic in vivo screen in mice identified P7C3 aminopropyl carbazole as capable of enhancing the net magnitude of postnatal neurogenesis by protecting young neurons from death. Subsequently, neuroprotective efficacy of P7C3 compounds in a broad spectrum of preclinical rodent models has also been observed. An important next step in translating this work to patients is to determine whether P7C3 compounds exhibit similar efficacy in primates. Adult male rhesus monkeys received daily oral P7C3-A20 or vehicle for 38 weeks. During weeks 2–11, monkeys received weekly injection of 5′-bromo-2-deoxyuridine (BrdU) to label newborn cells, the majority of which would normally die over the following 27 weeks. BrdU+ cells were quantified using unbiased stereology. Separately in mice, the proneurogenic efficacy of P7C3-A20 was compared to that of NSI-189, a proneurogenic drug currently in clinical trials for patients with major depression. Orally-administered P7C3-A20 provided sustained plasma exposure, was well-tolerated, and elevated the survival of hippocampal BrdU+ cells in nonhuman primates without adverse central or peripheral tissue effects. In mice, NSI-189 was shown to be pro-proliferative, and P7C3-A20 elevated the net magnitude of hippocampal neurogenesis to a greater degree than NSI-189 through its distinct mechanism of promoting neuronal survival. This pilot study provides evidence that P7C3-A20 safely protects neurons in nonhuman primates, suggesting that the neuroprotective efficacy of P7C3 compounds is likely to translate to humans as well.

AB - There is a critical need for translating basic science discoveries into new therapeutics for patients suffering from difficult to treat neuropsychiatric and neurodegenerative conditions. Previously, a target-agnostic in vivo screen in mice identified P7C3 aminopropyl carbazole as capable of enhancing the net magnitude of postnatal neurogenesis by protecting young neurons from death. Subsequently, neuroprotective efficacy of P7C3 compounds in a broad spectrum of preclinical rodent models has also been observed. An important next step in translating this work to patients is to determine whether P7C3 compounds exhibit similar efficacy in primates. Adult male rhesus monkeys received daily oral P7C3-A20 or vehicle for 38 weeks. During weeks 2–11, monkeys received weekly injection of 5′-bromo-2-deoxyuridine (BrdU) to label newborn cells, the majority of which would normally die over the following 27 weeks. BrdU+ cells were quantified using unbiased stereology. Separately in mice, the proneurogenic efficacy of P7C3-A20 was compared to that of NSI-189, a proneurogenic drug currently in clinical trials for patients with major depression. Orally-administered P7C3-A20 provided sustained plasma exposure, was well-tolerated, and elevated the survival of hippocampal BrdU+ cells in nonhuman primates without adverse central or peripheral tissue effects. In mice, NSI-189 was shown to be pro-proliferative, and P7C3-A20 elevated the net magnitude of hippocampal neurogenesis to a greater degree than NSI-189 through its distinct mechanism of promoting neuronal survival. This pilot study provides evidence that P7C3-A20 safely protects neurons in nonhuman primates, suggesting that the neuroprotective efficacy of P7C3 compounds is likely to translate to humans as well.

UR - http://www.scopus.com/inward/record.url?scp=85054054012&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85054054012&partnerID=8YFLogxK

U2 - 10.1038/s41398-018-0244-1

DO - 10.1038/s41398-018-0244-1

M3 - Article

C2 - 30258178

AN - SCOPUS:85054054012

VL - 8

JO - Translational Psychiatry

JF - Translational Psychiatry

SN - 2158-3188

IS - 1

M1 - 202

ER -